Joint pain is one of the things people on GLP-1 medications sometimes notice changing — and it does not always change the same way. Some people describe less discomfort over time, often as body weight shifts; others notice new aching or stiffness after starting. Tracking what you observe, and when, can make those provider conversations much more grounded and useful.
Why Joint Pain Comes Up on a GLP-1
Two distinct stories appear when people search this topic, and at first glance they can seem to contradict each other.
One account: some people experience joint pain as a side effect — new aching or stiffness that was not present before starting the medication. This pattern tends to come up more often during the earlier months.
The other account: some people notice less joint discomfort over time, particularly after meaningful weight changes. The reasoning behind this is largely mechanical. When the body carries less weight, the load on joints — particularly the knees and hips — may decrease with each step and each movement.
Both patterns occur. For different people, at different points in their journey, either experience may emerge.
A few possible contributors that have been discussed in research:
- Mechanical load reduction: For people with obesity, weight-bearing joints absorb force that scales with body weight. As weight decreases, that force per step may decline as well. This is one area that has received attention in studies looking at the relationship between weight loss and joint conditions.
- Activity level shifts: Some people move more as their energy and stamina change, which can affect joints differently depending on how the body adjusts to new patterns of movement.
- Possible broader effects: There is ongoing investigation into whether GLP-1 medications may have effects beyond weight loss itself — including effects on metabolic or inflammatory processes. This research is still evolving, and no specific outcome can be assumed for any individual.
- Muscle and joint interaction: Muscle function and joint feel are closely connected. For more on how muscle may be affected during GLP-1 treatment, the article on GLP-1 and muscle loss goes into what the evidence suggests.
None of these mechanisms have been confirmed to play out the same way in every person. Talk to your provider about what is most likely relevant to your specific situation.
What the Research Has Looked At
The most direct clinical evidence in this area comes from a 68-week randomized controlled trial specifically designed to enroll adults with obesity and a clinical and radiological diagnosis of knee osteoarthritis.
The trial assigned 407 participants in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or a placebo, alongside counseling on physical activity and a reduced-calorie diet. Participants, investigators, and study staff were blinded to the treatment assignment. This was a double-blind, placebo-controlled, multicenter design conducted across 61 sites in 11 countries.
At week 68, WOMAC knee pain scores among participants who received the study treatment showed a mean change of −41.7 points, compared with −27.5 points among those who received placebo — a difference that was statistically significant (P<0.001). This trial, known as STEP 9, was published by Bliddal et al. in the New England Journal of Medicine (2024;391:1573–1583; doi:10.1056/NEJMoa2403664).
What the findings describe — and what they do not
What the trial found: In a randomized, controlled study of adults who had both obesity and a diagnosed knee condition, those in the semaglutide arm saw meaningfully greater reductions in knee pain scores over 68 weeks compared with those in the placebo group.
What the trial does not establish:
- That everyone on this class of medication will notice the same result — the enrolled population had specific characteristics
- That these findings extend to joints other than the knee, or to people without a clinical diagnosis of osteoarthritis
- That the pain reduction resulted solely from the medication rather than from weight loss, lifestyle changes, or placebo response
- That individual results will match the group-level averages from a clinical trial
Beyond this specific trial, research on weight loss and joint load more broadly has looked at the relationship between body weight and mechanical stress on the joints. These studies suggest that joint load may decrease as weight decreases, though individual variation is considerable and no specific outcome can be anticipated in advance.
For a broader look at what to expect in the months that tend to show more physical changes, months 3 to 6 on a GLP-1 covers some of what people track over that period.
What Some People Report Noticing
People on GLP-1 medications describe a wide range of joint-related experiences, and these accounts vary considerably from person to person.
Some people describe changes they associate with weight loss and reduced physical load:
- Morning stiffness that seems less noticeable than it was at the start
- Longer walking distances feeling more manageable
- Less discomfort navigating stairs or getting up from a chair
- A general sense that certain movements feel different — sometimes easier, sometimes just different
These kinds of observations tend to come up more among people who have also experienced meaningful shifts in body weight. For a broader look at the kinds of changes people track that are not reflected on the scale — including mobility, energy, and other areas — non-scale victories on a GLP-1 covers more of that territory.
Other people describe a different experience:
- New joint aching or stiffness that appeared after starting the medication
- Soreness in joints that had not been a problem before
- Discomfort that is difficult to attribute to any specific activity or cause
- Variability from week to week without a clear pattern emerging
The honest answer from the research is that it has not clearly resolved which individuals are more likely to experience which pattern, or why responses differ so much. Joint discomfort appears in some medication labeling as a potential adverse effect, and at the same time the clinical literature includes trials that found significant pain reductions in specific populations.
This is part of why tracking your own experience matters. Your observations across multiple weeks — which joint, when it happens, how it changes — give your provider something specific and concrete to work with, rather than a general impression formed from memory.
Joint Pain That Is Worth a Call to Your Provider
This section is not a diagnostic checklist — determining what to act on, and how quickly, is something to work out directly with your provider. The article on GLP-1 side effects and when to contact your provider goes into that ground in more detail.
That said, a few patterns tend to prompt people to reach out sooner rather than waiting for a scheduled appointment:
- Joint pain that comes on suddenly and feels severe
- Swelling, redness, or warmth around a joint
- Pain that makes it difficult to bear weight on a limb or to use the affected joint normally
- New joint symptoms that seem to follow a consistent pattern tied to your injection schedule
If joint discomfort is making daily activities significantly harder — walking, climbing stairs, normal household tasks — that is worth raising with your provider, whether at the next visit or sooner if it is worsening quickly.
Your provider is in the best position to determine whether what you are experiencing may be connected to the medication, to changes in weight and activity, to a pre-existing condition, or to something unrelated. Having a record of what you have noticed — location, timing, intensity — makes that conversation much more productive than relying on memory alone.
Worth a call to your provider
Joint pain that is sudden, severe, or accompanied by swelling — contact your provider without waiting for the next scheduled visit.
What Is Worth Tracking to Bring to Your Provider
The most useful record is a specific one. Vague descriptions — “things have been off” or “joints ache sometimes” — are harder for a provider to act on than a consistent log with a few weeks of data behind it.
Things worth capturing as you go:
- Which joint or joints: Knee, hip, ankle, shoulder, fingers — location is important for interpretation
- Timing: Does it happen in the morning? After a specific activity? Around the time of your injection? During or after exercise?
- Intensity: A simple 0–10 numeric scale, noted at roughly the same time each day, gives a usable trend even if the individual numbers are imprecise
- Duration: Does the discomfort last a few minutes, several hours, or most of the day?
- What seems to affect it: Movement, rest, heat, ice — what appears to make things better or worse?
- Context: Did your activity level change? Did your eating patterns shift significantly? Did you add a new supplement or medication?
A few weeks of notes like these can reveal patterns that neither you nor your provider would have picked up from memory — timing in relation to weight changes, for example, or a correlation with a particular type of activity.
The GLP-1 tracking tool on this site is one option for keeping this kind of log in one place, alongside other observations from your journey. For a broader overview of what tends to be worth documenting and bringing to appointments, how to track GLP-1 side effects covers more of this practical ground.
Questions That Tend to Come Up at Appointments
People arrive at appointments with questions that formed across the weeks since their last visit. A few joint-related ones tend to come up often.
“Is this from the medication, or from the weight loss?”
This is genuinely difficult to separate, and your provider will likely want specific details — which joint, when the symptoms started, how they have changed — before forming an interpretation. Both mechanisms are plausible for different people, and they are not always easy to distinguish from the outside.
“Should I be exercising through this?”
The answer tends to depend on the nature and severity of what you are experiencing, and your provider is the right person to advise based on your specific situation. For a broader discussion of movement and GLP-1 medications, GLP-1 and physical activity addresses some of what people commonly ask about.
“Could this be related to muscle changes?”
Possibly. Muscle function and joint feel are closely linked, and some shifts in how joints move or feel may be related to changes in the muscles that support them. For more on what the research has looked at regarding muscle on a GLP-1, GLP-1 and muscle loss goes into that in more detail.
“Is this a sign I’ve reached a plateau?”
Weight changes and joint symptoms do not always track together directly. Plateaus in weight loss are common and happen for reasons that are not always connected to joint experiences. For more on what plateaus tend to look like and what tends to happen next, GLP-1 and weight loss plateaus covers that territory.